Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA

Autor: Smolen, J.S., Boers, M., Abadie, E.C., Breedveld, F.C., Emery, P., Bardin, T., Goel, N., Ethgen, D.J., Avouac, B.P., Dere, W.H., Durez, P., Matucci-Cerinic, M., Flamion, B., Laslop, A., Lekkerkerker, F.J., Miossec, P., Mitlak, B.H., Ormarsdottir, S., Paolozzi, L., Rao, R., Reiter, S., Tsouderos, Y., Reginster, J.Y., GREES

Publikováno v: Current Medical Research and Opinion, 27(2), 315-325. Taylor and Francis Ltd.
Current Medical Research and Opinion, 27(2), 315-325
Smolen, J S, Boers, M, Abadie, E C, Breedveld, F C, Emery, P, Bardin, T, Goel, N, Ethgen, D J, Avouac, B P, Dere, W H, Durez, P, Matucci-Cerinic, M, Flamion, B, Laslop, A, Lekkerkerker, F J, Miossec, P, Mitlak, B H, Ormarsdottir, S, Paolozzi, L, Rao, R, Reiter, S, Tsouderos, Y & Reginster, J Y 2011, ' Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA ', Current Medical Research and Opinion, vol. 27, no. 2, pp. 315-325 . https://doi.org/10.1185/03007995.2010.542135

Since 2003, the European Medicines Agency (EMA) document, 'Points to consider on clinical investigation of medicinal products other than NSAIDs (nonsteroidal anti-inflammatory drugs) for the treatment of rheumatoid arthritis' has provided guidance fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28104144863cc32f0fc77ce01f4a892f
https://doi.org/10.1185/03007995.2010.542135

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.